Opgenorth A, Graham K, Nation N, Strayer D, McFadden G
Department of Biochemistry, University of Alberta, Edmonton, Canada.
J Virol. 1992 Aug;66(8):4720-31. doi: 10.1128/JVI.66.8.4720-4731.1992.
Myxoma virus (MYX) is a leporipoxvirus of rabbits that induces a lethal syndrome characterized by disseminated tumorlike lesions, generalized immunosuppression, and secondary gram-negative bacterial infection. A MYX deletion mutant (vMYX-GF- delta M11L) was constructed to remove the entire myxoma growth factor (MGF) coding sequence and that for the C-terminal five amino acids of the partially overlapping upstream gene, M11L. Unexpectedly, this deletion completely abrogates the capacity of MYX to cause the characteristic disease symptoms of myxomatosis. Upon inoculation of rabbits with vMYX-GF- delta M11L, recipient animals developed only a benign, localized nodule reminiscent of a Shope fibroma virus-induced tumor in which a single primary lesion appeared at the site of injection and then completely regressed within 14 days, leaving the animals resistant to challenge with wild-type MYX. No evidence of the purulent conjunctivitis and rhinitis that always accompany wild-type MYX infection was observed. To ascertain whether the attenuation observed in vMYX-GF- delta M11L was due to a combined effect of the MGF deletion and alteration of the upstream M11L gene, two additional MYX recombinants were constructed: an MGF- virus (vMYX-GF-) containing an intact M11L gene and an M11L- virus (vMYX-M11L-) containing an intact MGF gene. Infection with vMYX-GF- resulted in moderated symptoms of myxomatosis, but all clinical stages of the disease were still detectable. In contrast, disruption of M11L alone dramatically reduced the virus virulence, resulting in a nonlethal syndrome whose clinical course was nevertheless distinct from that of vMYX-GF- delta M11L. Upon inoculation with vMYX-M11L-, rabbits developed primary and secondary tumors which were larger and more circumscribed than those of wild-type MYX recipients. Whereas wild-type MYX infection always includes severe, purulent conjunctivitis and rhinitis, vMYX-M11L- recipients remained healthy and displayed only minimal signs of respiratory distress. By about 30 days after infection, the tumors induced by vMYX-M11L- had completely regressed and these animals were immune to challenge with wild-type MYX. Histological analysis indicated that tumors induced by vMYX-M11L- are much more heavily infiltrated with macrophages and heterophils and that the sites of viral replication are more edematous and necrotic than those of wild-type infection, suggesting that the host was able to mount a more vigorous inflammatory response to vMYX-M11L- infection.(ABSTRACT TRUNCATED AT 400 WORDS)
黏液瘤病毒(MYX)是一种兔的兔痘病毒,可诱发一种致死性综合征,其特征为弥漫性肿瘤样病变、全身性免疫抑制以及继发性革兰氏阴性菌感染。构建了一种MYX缺失突变体(vMYX-GF-ΔM11L),以去除整个黏液瘤生长因子(MGF)编码序列以及部分重叠的上游基因M11L的C末端五个氨基酸的编码序列。出乎意料的是,这种缺失完全消除了MYX引发黏液瘤病特征性疾病症状的能力。用vMYX-GF-ΔM11L接种兔子后,受体动物仅出现一个良性的局部结节,类似于肖普纤维瘤病毒诱导的肿瘤,其中在注射部位出现单个原发性病变,然后在14天内完全消退,使动物对野生型MYX的攻击具有抗性。未观察到野生型MYX感染时总是伴随的脓性结膜炎和鼻炎的迹象。为了确定在vMYX-GF-ΔM11L中观察到的减毒是否是由于MGF缺失和上游M11L基因改变的联合作用,构建了另外两种MYX重组体:一种含有完整M11L基因的MGF-病毒(vMYX-GF-)和一种含有完整MGF基因的M11L-病毒(vMYX-M11L-)。用vMYX-GF-感染导致黏液瘤病症状较轻,但该疾病的所有临床阶段仍可检测到。相比之下,单独破坏M11L会显著降低病毒毒力,导致一种非致死性综合征,但其临床病程与vMYX-GF-ΔM11L不同。用vMYX-M11L-接种后,兔子出现原发性和继发性肿瘤,这些肿瘤比野生型MYX受体的肿瘤更大且边界更清晰。野生型MYX感染总是包括严重的脓性结膜炎和鼻炎,而vMYX-M11L-受体保持健康,仅表现出轻微的呼吸窘迫迹象。感染后约30天,vMYX-M11L-诱导的肿瘤已完全消退,这些动物对野生型MYX的攻击具有免疫力。组织学分析表明,vMYX-M11L-诱导的肿瘤中巨噬细胞和异嗜性粒细胞浸润更为严重,病毒复制部位比野生型感染的部位水肿和坏死更严重,这表明宿主能够对vMYX-M11L-感染产生更强烈的炎症反应。(摘要截断于400字)